Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBT (2021 - 2025)

Kezar Life Sciences' EBT history spans 5 years, with the latest figure at -$10.7 million for Q3 2025.

  • For Q3 2025, EBT rose 47.38% year-over-year to -$10.7 million; the TTM value through Sep 2025 reached -$61.2 million, up 36.14%, while the annual FY2024 figure was -$83.7 million, 17.8% up from the prior year.
  • EBT for Q3 2025 was -$10.7 million at Kezar Life Sciences, up from -$13.7 million in the prior quarter.
  • Across five years, EBT topped out at -$10.7 million in Q3 2025 and bottomed at -$32.3 million in Q4 2023.
  • The 5-year median for EBT is -$17.8 million (2022), against an average of -$18.4 million.
  • The largest annual shift saw EBT crashed 77.44% in 2023 before it soared 47.38% in 2025.
  • A 5-year view of EBT shows it stood at -$14.2 million in 2021, then dropped by 27.93% to -$18.2 million in 2022, then plummeted by 77.44% to -$32.3 million in 2023, then soared by 37.33% to -$20.2 million in 2024, then skyrocketed by 47.13% to -$10.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's EBT are -$10.7 million (Q3 2025), -$13.7 million (Q2 2025), and -$16.6 million (Q1 2025).